Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting-Reference-Cited by-同舟云学术

Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting

Published:2020-03-01 Issue:3 Volume:83 Page:240-250
ISSN:1525-4135
Container-title:JAIDS Journal of Acquired Immune Deficiency Syndromes
language:en
Short-container-title:

Author:

Greenberg Lauren,Ryom Lene,Wandeler Gilles,Grabmeier-Pfistershammer Katharina,Öllinger Angela,Neesgaard Bastian,Stephan Christoph,Calmy Alexandra,Rauch Andri,Castagna Antonella,Spagnuolo Vincenzo,Johnson Margaret,Stingone Christof,Mussini Cristina,De Wit Stéphane,Necsoi Coca,Campins Antoni A.,Pradier Christian,Stecher Melanie,Wasmuth Jan-Christian,Monforte Antonella d'Arminio,Law Matthew,Puhr Rainer,Chkhartishvilli Nikoloz,Tsertsvadze Tengiz,Garges Harmony,Thorpe David,Lundgren Jens D.,Peters Lars,Bansi-Matharu Loveleen,Mocroft Amanda,

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Infectious Diseases

Reference43 articles.

1. Raltegravir with optimized background therapy for resistant HIV-1 infection;Steigbigel;N Engl J Med.,2008

2. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials;Eron;Lancet Infect Dis.,2013

3. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks;Sax;Lancet.,2012

4. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-;DeJesus;Lancet.,2012

5. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet.,2013

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic Liver Enzyme Elevation and Use of Contemporary ARVs Among People With HIV;Open Forum Infectious Diseases;2024-06

2. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care;HIV/AIDS - Research and Palliative Care;2024-04

3. Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting;Journal of Antimicrobial Chemotherapy;2023-10-24

4. Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV;Cancers;2023-07-15

5. Real-world discontinuations due to neuropsychiatric symptoms in people living with HIV treated with second-generation integrase inhibitors: a systematic review;Expert Review of Anti-infective Therapy;2023-04-20